glp-1 for migraine A drug originally designed to treat obesity is now showing surprising promise in the fight against migraines. In a recent early-stage clinical trial, the receptor agonist liraglutide from the same family GLP-1 diabetes drugs like Ozempic

It promotes angiogenesis by increasing VEGF expression, enhances nitric oxide production for improved blood flow, and upregulates growth factor receptors (including ERK1/2 and AKT signaling) in damaged tissue

Nair S, Huynh JP, Lampropoulou V, Loginicheva E, Esaulova E, Gounder AP, Boon ACM, Schwarzkopf EA, Bradstreet TR, Edelson BT, et al

All products are intended strictly for laboratory research purposes only Credit card payments will be available again soon

It doesn't help because the problem isn't on the surface

In addition, the SUMMIT trial evaluates the effect of tirzepatide (the GLP-1/GIP dual receptor agonist) in people with obesity-related HFpEF (Clinicaltrials.gov ID NCT04847557)